Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema 2.4 mg/2.4 mg) once weekly versus semaglutide 2.4 mg, cagrilintide 2.4 mg and placebo in people with chronic kidney disease and type 2 diabetes living with overweight or obesity.

This study is a medical research project trying to find new and better ways to help people who have type 2 diabetes and chronic kidney disease, especially if they also struggle with being overweight or obese. The main focus is on a new medicine called CagriSema. This isn't just one medicine, but a combination of two existing treatments, cagrilintide and semaglutide, given together in one weekly dose. Researchers want to see if this combination works better than taking each medicine separately, or compared to a 'placebo' – which is a dummy medicine containing no active ingredients.

The health of your kidneys is an important part of this study. The researchers will be looking closely at how the new medicine affects a measure called UACR (which checks for protein in your urine, a sign of kidney damage) and eGFR (which tells us how well your kidneys are filtering waste). They'll also be tracking other important health markers like changes in body weight, how much sugar is in your blood (measured by HbA1c), and your blood pressure. By checking all these things, the study aims to get a full picture of how CagriSema might help manage these complex health conditions.

Ultimately, this research is about improving treatment options. By carefully comparing CagriSema to other treatments and a placebo, medical experts hope to learn if this new combination could be a more effective way to help people with type 2 diabetes, kidney disease, and overweight or obesity to live healthier lives. Safety is always a top priority, so any side effects will be recorded and examined very carefully.